Efficacy
DISEASE
As of 1 September 2022, the median OS follow-up duration reached 12.3 months (IQR 3.4–33.4) (Duration of response Among the 33 pts in this study, the objective response rate assessed by the investigator per RECIST 1.1 was 63.6% (95%CI 44.6–77.8), with 2 (6.1%) confirmed complete response (CR) and 19 (57.6%) confirmed partial response (PR).The disease control rate (DCR) was 90.9% (95%CI: 76.4–96.9), and the median time to response (mTTR) was 2.4 months (As is shown in Supplement, one-way ANOVA analysis showed that no factor influenced the OS. The Neutrophil-to-lymphocyte ratio, PFS Objective response and disease response.In this study, the subjects voluntarily underwent programmed death-ligand 1 (PD-L1) expression testing, and a total of 23 cases were PD-L1 positive, 7 cases were negative, and 3 cases were unknown. According to the test results, patients were divided into the PD-L1-positive group (23 cases) and PD-L1-negative or unknown group (10 cases) for analysis. The mPFS of the two groups were 11.83 (5.29, 25.6) and 8.54 (1.23, NA), and the OS were 23.1 (11.53, NA) and 12.5 (3.81, NA), respectively (